Calcitonin Gene-Related Peptide For The Reduction Of Allergen-Induced Airway Hyperresponsiveness
Treatment of AHR
Treatment of AHR
Administration of CGRP to sensitized and challenged mice resulted in the normalization of AHR.This potential therapy for AHR was tested in phase II of clinical trials however the trial was never completed.
Inventor: Cadieux, Alain
Priority Number: US6743429B2
IPC Current: A61K003823
US Class: 4241981 | 5140119 | 514826 | 514012
Assignee Applicant: Sherbrooke University,Quebec
Title: Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
Usefulness: Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
Summary: CGRP and its natural homolog (their fragments, analogs or derivatives) are useful for the prevention or alleviation of asthma, bronchospastic disease characterized by airway hyperreactivity or lung inflammatory reaction characterized by increased eosinophilia (claimed).
Novelty: Use of calcitonin gene-related peptide for preventing, reducing and/or alleviating bronchospastic airway diseases, especially reversible airway hyperreactivity and lung inflammation encountered in asthma
生物醫學
醫藥成分
美國
